John Patlan
Internal Medicine · Houston, TXNPI 1629162656
Payments from drug & device makers
Across 294 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$585
- Amarin Pharma, Inc.$512
- Lilly USA, LLC$338
- Boehringer Ingelheim$271
- Merck$247
- plus $2K from 20 others
What the payments were for
- Food & beverage$4,648100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 67 | $1,091 |
| AstraZeneca | 34 | $585 |
| Amarin Pharma, Inc. | 30 | $512 |
| Lilly USA, LLC | 26 | $338 |
| Boehringer Ingelheim | 17 | $271 |
| Merck | 20 | $247 |
| Astellas Pharma US Inc | 12 | $198 |
| Pfizer | 11 | $197 |
| GSK | 11 | $188 |
| Abbott | 7 | $135 |
| Teva Pharmaceuticals USA, Inc. | 8 | $113 |
| AbbVie(2 entities) | 7 | $111 |
| Johnson & Johnson | 8 | $108 |
| Novartis | 6 | $98 |
| Cranial Technologies, Inc | 6 | $82 |
| Genentech USA, Inc. | 4 | $54 |
| Arbor Pharmaceuticals, Inc. | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Gilead | 3 | $39 |
| Sanofi Pasteur Inc. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Dynavax Technologies Corporation | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Amgen | 2 | $29 |
| Bayer | 1 | $19 |
| Evoke Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Saxenda$114
How this compares
$4,648 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 16 | $281 |
| Atorvastatin Calcium | 20 | $200 |
| Levothyroxine Sodium | 14 | $187 |
| Rosuvastatin Calcium | 13 | $167 |
| Amlodipine Besylate | 17 | $155 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Houston
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Nicholas ShortHouston$17.6M
- Isabella GlitzaHouston$14.8M
- Murtaza MussajiHouston$13.1M
- Hussein TawbiHouston$12.6M
- Hans LeeHouston$11.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.